JAMA Oncology Author Interviews podcast

Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in ERBB2-Positive Breast Cancer

0:00
13:01
15 Sekunden vorwärts
15 Sekunden vorwärts

Weitere Episoden von „JAMA Oncology Author Interviews“